| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.16(B) |
| Last
Volume: |
3,620,965 |
Avg
Vol: |
4,460,019 |
| 52
Week Range: |
$4.13 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14 |
| Insider 6 Months : 14 |
| Insider 3/6 Months : 27.5 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
153,240 |
153,240 |
153,240 |
153,240 |
| Total Buy Value |
$856,692 |
$856,692 |
$856,692 |
$856,692 |
| Total People Bought |
6 |
6 |
6 |
6 |
| Total Buy Transactions |
6 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Milano Vincent |
Director |
• • – |
2023-02-28 |
4 |
A |
$8.85 |
$5,620 |
D/D |
635 |
31,826 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2023-02-28 |
4 |
A |
$8.85 |
$19,992 |
D/D |
2,259 |
100,198 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-02-01 |
4 |
AS |
$10.38 |
$1,038,000 |
D/D |
(100,000) |
1,008,739 |
|
-21% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-02-01 |
4 |
OE |
$5.45 |
$545,000 |
D/D |
100,000 |
1,108,739 |
|
- |
|
| Lee Kenneth B Jr |
Director |
• • – |
2023-01-31 |
4 |
OE |
$1.71 |
$25,650 |
D/D |
15,000 |
52,118 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
10,000 |
10,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
1,008,739 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
81,000 |
214,275 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
245,610 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
232,770 |
|
- |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
16,653 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
127,500 |
1,015,230 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
197,966 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2022-12-15 |
4 |
AS |
$10.88 |
$45,424 |
D/D |
(4,175) |
198,770 |
|
-30% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-15 |
4 |
AS |
$10.90 |
$153,690 |
D/D |
(14,100) |
887,730 |
|
-30% |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2022-12-15 |
4 |
AS |
$10.89 |
$34,031 |
D/D |
(3,125) |
133,275 |
|
-30% |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-12-15 |
4 |
AS |
$10.90 |
$4,851 |
D/D |
(445) |
10,753 |
|
-30% |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2022-12-15 |
4 |
AS |
$10.90 |
$62,130 |
D/D |
(5,700) |
163,966 |
|
-30% |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2022-12-15 |
4 |
AS |
$10.90 |
$66,490 |
D/D |
(6,100) |
211,610 |
|
-30% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-02 |
4 |
AS |
$12.80 |
$1,057,997 |
D/D |
(82,656) |
901,830 |
|
-37% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-02 |
4 |
OE |
$1.42 |
$117,372 |
D/D |
82,656 |
984,486 |
|
- |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-12-01 |
4 |
S |
$13.01 |
$111,886 |
D/D |
(8,600) |
11,198 |
|
35% |
|
| Jones Michael L |
Exec. Director, Finance - PAO |
• • – |
2022-12-01 |
4 |
OE |
$1.42 |
$12,212 |
D/D |
8,600 |
19,798 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-01 |
4 |
AS |
$13.00 |
$2,793,921 |
D/D |
(214,917) |
901,830 |
|
-35% |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2022-12-01 |
4 |
OE |
$1.42 |
$305,182 |
D/D |
214,917 |
1,116,747 |
|
- |
|
737 Records found
|
|
Page 3 of 30 |
|
|
0.15 (2.39%) 
